Abstract
A considerable amount of literature has demonstrated that eukaryotic translation elongation factor 1A (eEF1A) is closely related to tumors. As a newly identified lysine specific methyltransferase targeting eEF1A at Lys-165, too little attention has been paid to the function of METTL21B. To determine the potential significance and prognostic value of METTL21B in low grade glioma (LGG), we analyzed the expression, methylation level and copy number variations (CNV) of METTL21B and its effect on prognosis in patients with LGG by 4 public databases in conjunction with experimental examination of LGG patient samples. As a result, we found that high expression, hypomethylation and gain/amplification of CNV of METTL21B were associated with poor prognosis in LGG. The potential functions of METTL21B in LGG may be involved in cell adhesion, angiogenesis and cell proliferation of tumor by enrichment analysis. In addition, METTL21B may facilitate immune evasion of tumor and affect prognosis by mediating macrophage polarization from M1 to M2 and regulating expression of immune checkpoints. Nevertheless, patients with high METTL21B level are likely to have better response to immune checkpoints blockage therapy. Because of its substrate specificity, METTL21B is expected to be a promising target for the treatment of glioma.
Highlights
Arising from glial cells, glioma is a type of primary neoplasms of center nervous system (CNS) system in adults, with the highest morbidity and mortality [1]
The data indicated that mRNA expression of METTL21B in low grade glioma (LGG) was significantly up-regulated compared with normal tissues (Figure 1A)
By analyzing the association between METTL21B expression and clinical features including age, gender, race and World Health Organization (WHO) grade, we found that WHO grade III glioma has higher expression level of METTL21B compared with WHO grade II (Figure 2), which www.aging-us.com indicates that METTL21B could be related to malignant behaviors of LGG
Summary
Arising from glial cells, glioma is a type of primary neoplasms of center nervous system (CNS) system in adults, with the highest morbidity and mortality [1]. The patients with LGG had a longer survival time compared with glioblastoma (GBM, WHO grade IV), its high postoperative recurrence and mortality rates are still significant concerns [3]. More than half of LGG patients died of recurrence and progression [4]. Despite the developments of treatment for LGG in recent years, some tumors still showed therapeutic resistance and even progressed to GBM [5, 6]. Genetic heterogeneity of LGG is considered as the main reason of different treatment responses and widely variable prognosis [3, 7]. Some recent research reported that MGMT promoter methylation, TERT promoter mutation, TLX1NB, ARL9 and 1p/19q deletion are association with prognosis of patients with LGG [10,11,12,13,14]. Identification of molecular biomarkers is www.aging-us.com unquestionably essential and urgent for accurately predicting prognosis and for seeking critical therapeutic targets in LGG
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
